Loading...
NASDAQ: AMGN
Amgen Inc.
Healthcare · Drug Manufacturers - General
●S&P 500 since 1992
Market Cap
$190.49B
52w High
$391.29
52w Low
$261.43
P/E
24.70
Volume
276.91K
Outstanding Shares
539.07M
Company profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
CEORobert A. Bradway
SectorHealthcare
IndustryDrug Manufacturers - General
Employees28,000
IPO dateJun 17, 1983
Valuation
Forward P/E—
EV/EBITDA13.99
Enterprise value$221.57B
Stock splits
Nov 22, 19992:1
Mar 1, 19992:1
Aug 16, 19952:1
Sep 11, 19913:1
Aug 13, 19902:1
Profitability & growth
Revenue growth8.91%
Gross margin70.49%▲15.06%vs FY2024
Operating margin27.99%▲33.81%vs FY2024
ROE89.06%▲27.98%vs FY2024
Analyst consensus
RatingBuy
Target price$347.73▼1.60%
22
Buy
12
Hold
3
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$6.02
$5.28
Q3FY25
ActualEst.
$5.64
$5.02
Q4FY25
ActualEst.
$5.29
$4.73
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$9.17B
$8.94B
Q3FY25
ActualEst.
$9.56B
$8.97B
Q4FY25
ActualEst.
$9.9B
$9.47B
Q1FY26
Next Est.
—